Posted by Michael Wonder on 05 May 2022
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over
5 May 2022 - NICE has published evidence based recommendations on the use of selumetinib (Koselugo) for the treatment of children aged 3 and over with symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis.
Selumetinib is recommended for the treatment of children aged 3 and over with symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis only if AstraZeneca provides selumetinib according to the commercial arrangement.
